Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
前日終値
$16.11
+$0.435 · +2.78%
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
47
適正価値
センチメント
70
強気
リスク
70
高リスク
モメンタム
30
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
日中レンジ
現在 $16.11
52週レンジ
現在 $16.11
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 10.15億 USD | 9.4億 USD | 7.48億 USD | 8.01億 USD | 7.03億 USD |
| 売上原価 | 4.84億 USD | 4.51億 USD | 3.8億 USD | 3.88億 USD | 3.27億 USD |
| 粗利益 | 5.31億 USD | 4.9億 USD | 3.68億 USD | 4.13億 USD | 3.76億 USD |
| 研究開発 | 1.75億 USD | 1.99億 USD | 2.48億 USD | 1.7億 USD | 9205.4万 USD |
| 販売・一般管理 | 4.34億 USD | 3.9億 USD | 3.53億 USD | 3.36億 USD | 2.62億 USD |
| 営業費用 | 6.09億 USD | 5.89億 USD | 6.01億 USD | 5.06億 USD | 3.54億 USD |
| 受取利息 | 908.6万 USD | 1799.3万 USD | 2285.8万 USD | 605.7万 USD | 67.4万 USD |
| 支払利息 | 790.7万 USD | 741.5万 USD | 988.2万 USD | 620.8万 USD | 604万 USD |
| 減価償却費と償却費 | 1766.6万 USD | 1660.7万 USD | 1571.5万 USD | 1433万 USD | 1384.5万 USD |
| 営業利益 | −7812.2万 USD | −9912.7万 USD | −2.33億 USD | −9284.8万 USD | 2265.3万 USD |
| 純利益 | −2.05億 USD | −9602.5万 USD | −2.23億 USD | −9459.4万 USD | 1556.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。